New Paclitaxel Nanoparticle Delivery Improves Cancer Treatment Results

作者
Lindsey Nolen
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:48 (4): 29-30
标识
DOI:10.1097/01.cot.0000000000000331
摘要

Paclitaxel has long been a cornerstone chemotherapeutic agent in the treatment of several cancers, including breast and pancreatic malignancies. However, its potential is known to be limited by poor solubility and inefficient tumor delivery. Published in Nature Cancer (2025; doi.org/10.1038/s43018-025-01029-7), a new study details how researchers at the University of Arizona have developed a sphingolipid-derived paclitaxel nanovesicle, called the “paclitaxome,” that significantly improves pharmacokinetics, enhances tumor penetration, and reduces systemic toxicity in preclinical models. Led by Jianqin Lu, PhD, John A. and Frances P. Ware Endowed Associate Professor of Pharmaceutical Sciences at the University of Arizona R. Ken Coit College of Pharmacy, the research team demonstrated that this nanovesicle formulation outperformed the two FDA-approved paclitaxel products, Taxol and Abraxane, in both triple-negative breast cancer (TNBC) and pancreatic cancer models. According to Lu, the discovery represents a step toward safer and more effective drug delivery systems for difficult-to-treat cancers. He explained that one of the primary goals was to minimize adverse reactions that often accompany paclitaxel-based treatments. Designing a Smarter Nanocarrier Historically, traditional paclitaxel formulations have faced a trade-off between solubility and safety. Taxol uses Cremophor EL and ethanol as solubilizers but causes hypersensitivity reactions. Alternatively, Abraxane, an albumin-bound nanoparticle, offers a better safety profile but limited improvements in efficacy. To overcome these challenges, Lu's team engineered a self-assembling nanovesicle by conjugating paclitaxel to sphingomyelin, a natural phospholipid found in mammalian cell membranes. The chemical attachment created a stable bilayer structure that improved the drug's solubility, stability, and loading capacity. “Our paclitaxel is still a liposome formulation. So the difference compared to the traditional liposome is, in traditional liposome, the drug is physically encapsulated into the liposome,” Lu explained. “In our case, we chemically conjugate paclitaxel with a phospholipid or sphingolipid called sphingomyelin, so the drug is chemically attached into the bilayer of the liposome structure.” According to the study, the maximum tolerated dose (MTD) of paclitaxel increased from 20 mg/kg for Taxol and 40 mg/kg for paclitaxel physically laden liposome to as high as 70-100 mg/kg for the new paclitaxome. Of note, mice treated with the nanovesicle formulation exhibited minimal weight loss and no evidence of myelosuppression or neuropathy, two of paclitaxel's most problematic side effects. Improving Tumor Penetration & Drug Retention Despite higher drug loading and stability, Lu noted that nanocarriers often struggle to penetrate deeply into tumor tissue. The team addressed this limitation by engineering a cationization-enabled transcytosis mechanism through the integration of an ultra-pH-sensitive azepane (AZE) probe. The AZE probe responds to the mildly acidic tumor microenvironment (pH ~6.5) by reversing the surface charge of the nanovesicle from negative to positive. This charge conversion enhances adsorption-mediated endocytosis and transcytosis, allowing the nanocarrier to move more effectively through tumor layers. “The reason why we selected the azepane is because of its specific pKa,” Lu affirmed. “In the tumor microenvironment, the pH is acidic, around 6.5. Under that acidic pH, the AZE can be easily ionized and flip the charge from negative to positive. The positive-charged nanoparticle will interact with the negatively charged cancer-cell surface to enable this adsorption-mediated deep tumor penetration.” In cellular and three-dimensional tumor spheroid models, the AZE-enabled paclitaxome also demonstrated significantly improved uptake and diffusion compared to non–pH-responsive controls. As detailed in the study, the nanovesicle's internalization was primarily mediated through caveolae-dependent endocytosis, with trafficking through the Golgi apparatus facilitating efficient transcellular transport. “The major bottleneck for the tumor delivery of nanomedicine is in the tumor microenvironment,” Lu noted. “The interstitial fluid pressure induces strong resistance for drugs to transport or diffuse, and the extracellular matrix further blocks effective delivery.” He shared that the charge-reverse intelligent nanoparticle can facilitate this deep tumor penetration by overcoming those barriers, like interstitial fluid pressure and extracellular matrix. This then leads to more tumor uptake. Enhancing Circulation Time & Avoiding Immune Clearance Another major advancement in Lu's design was the use of a CD47 “self” peptide coating to replace traditional polyethylene glycol (PEG) shielding. While PEGylation has long been used to extend nanoparticle circulation times, repeated exposure can trigger anti-PEG immune responses that accelerate clearance. “CD47 is a protein that exists on the surface of red blood cells and other healthy cells. It sends a signal to macrophages that says, ‘Don't eat me,’” Lu explained. “So if we coat our nanoparticle with CD47 peptide, it can escape macrophage phagocytosis. That means it can stay in the circulation longer and deliver more drug to the tumor.” According to the research, the CD47-coated, pH-sensitive paclitaxome exhibited a 1.67-fold longer half-life and a 2.4-fold higher tumor drug accumulation compared to PEGylated versions. The combined AZE and CD47 modifications reduced drug distribution to non-tumor tissues, improving therapeutic selectivity and efficacy. Redefining Performance Among Nanocarriers When compared against leading paclitaxel formulations, including Taxol, Abraxane, and other experimental nanocarriers such as chimeric polypeptide–paclitaxel (CP-PTX) and poly(γ-l-glutamylglutamine)-paclitaxel (PGG-PTX), the CD47p/AZE-paclitaxome consistently demonstrated superior pharmacokinetics and antitumor activity. In a triple-negative breast cancer model (4T1-Luc2), the nanovesicle nearly eliminated tumor growth and metastasis to the lungs, the research states. In an advanced pancreatic cancer model (KPC-Luc), the formulation significantly extended survival and reduced metastatic burden compared with all other paclitaxel-based treatments. “Through the use of CD47 self peptide, we can reduce the distribution of the nanoparticle to healthy tissues,” Lu said. “So less of the chemotherapy drug reaches healthy tissues. That's one reason we can reduce toxicity at much higher doses. The chemical conjugation strategy also helps because it requires specific tumor stimuli to release the drug, which further reduces systemic toxicity.” Optimizing Combination Therapies Beyond monotherapy, Lu's team sought to test whether the paclitaxome platform could improve combination treatments, specifically paclitaxel plus gemcitabine for pancreatic cancer and paclitaxel plus carboplatin for TNBC. “Paclitaxel plus gemcitabine or paclitaxel plus carboplatin are standard care for treating breast cancer or pancreatic cancer,” Lu said. “That's why we want to co-deliver these two drugs with the paclitaxel platform. Through this chemical conjugation and physical loading, we can coordinate the drug release and achieve synergistic efficacy while reducing toxicity.” By identifying the optimal synergistic ratios (2:1 for paclitaxel to gemcitabine and 4:1 for paclitaxel to carboplatin), the researchers were able to encapsulate both drugs within the nanovesicle without compromising their stability or size. Co-encapsulation of gemcitabine and paclitaxel led to a 10.4-fold increase in half-life, a 230-fold increase in area under the curve, and nearly 30-fold higher tumor accumulation compared to conventional combination therapy. As presented in the research, these results correlated with significant reductions in metastatic lesions and enhanced survival. Further, in the postsurgical TNBC recurrence model, the co-delivery of paclitaxel and carboplatin with CD47p/AZE–paclitaxome reduced tumor regrowth to just 35% of its pre-surgical size and markedly extended survival. “We use chemical conjugation to attach the drug into a phospholipid that has been used in liposome formulation,” Lu said. “The nanocarrier itself is a drug. To have more effective combination chemotherapy, we just need to load the second drug through physical entrapment, which simplifies the process.” Proving the Platform Works Beyond Paclitaxel To test whether this approach could be generalized to other drugs, the team applied the same sphingomyelin, AZE, and CD47p design to camptothecin, another hydrophobic anticancer agent. The resulting formulation, termed “camptothesome,” showed improved stability, pH responsiveness, and tumor targeting. In mouse models of pancreatic cancer, the CD47p/AZE–camptothecin achieved higher tumor accumulation and outperformed free camptothecin and Onivyde, an FDA-approved liposomal irinotecan formulation. “I think this strategy is pretty versatile,” Lu said. “In addition to paclitaxel, we already extended this technology to other drugs like doxorubicin or platinum-based drugs. As long as the drug has a functional group like hydroxyl, carboxyl, or amine, we can easily attach it to the sphingomyelin because sphingomyelin has a hydroxyl group that enables drug conjugation.” The Pathway to Clinical Development While the current study was conducted in preclinical models, Lu believes the findings lay a strong foundation for future clinical development. “I think most nanoparticle formulations face one common issue with clinical translation, which is the scale-up,” Lu said. “We can optimize the design in small-scale, but that may not work for large batch production needed for clinical trials. We already launched large-scale preparation using ethanol injection technology and manufactured enough for about 100 patients.” Lu added that while manufacturing progress continues, his team is also exploring new therapeutic possibilities for the platform. The potential for the paclitaxome platform extends beyond oncology. The nanovesicle's ability to carry both small molecules and biologics means it could be adapted for use in other therapeutic areas where precise delivery and controlled release are essential. “In addition to oncology, we're actively investigating other diseases like Alzheimer's and Parkinson's,” Lu said. “Those are neurodegenerative diseases that require crossing the blood-brain barrier. We're also studying brain tumors like glioblastoma, which need deep tissue penetration for effective therapy.” Clinical Application Looking ahead, the study's findings could have broad implications for cancer treatment, particularly for tumors known to resist traditional chemotherapy. Lu emphasized that integrating targeted delivery with combination therapy may help overcome multiple barriers simultaneously. “Paclitaxel itself, although it's a chemo, also has immunogenic cell death potential,” Lu said. “That's a unique type of cancer cell death mechanism during which cytotoxic T cells can be recruited and activated in the tumor site. So that's how we can potentially synergize with other immunotherapy drugs like immune checkpoint inhibitors.” He explained that the combination of sphingolipid conjugation, pH-responsive cationization, and immune evasion through CD47 coating provides a versatile template for nanomedicine design. “What we found right now is paclitaxel tends to switch immune-cold TNBC and pancreatic cancer into a hot, inflamed type with many inflammatory molecules induced or activated in TNBC and pancreatic cancer,” Lu said. “That allows us to further enhance immune checkpoint inhibitor efficacy because we can specifically upregulate PD-1 and PD-L1 levels in these two immune-cold cancers.” Ultimately, Lu and his research team have developed a delivery system that enhances the efficacy and safety of paclitaxel-based therapies. The sphingolipid-derived paclitaxome improves tumor targeting, avoids immune clearance with CD47 coating, and enables safe co-delivery of multiple drugs. If successfully translated into the clinic, this innovation could reshape how oncologists approach combination chemotherapy for tumors that are notoriously hard to treat. The paclitaxome platform offers a promising framework for building the next generation of targeted nanomedicines that deliver higher precision and improved patient outcomes. Lindsey Nolen is a contributing writer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
haitun完成签到,获得积分10
1秒前
炫彩小陈发布了新的文献求助10
1秒前
Lucas的应助被兴奋的煎饼采纳,获得10
1秒前
田様的应助被程汁采纳,获得10
1秒前
gzsy发布了新的文献求助10
1秒前
Liangang完成签到,获得积分10
1秒前
2秒前
惜梦完成签到 ,获得积分10
2秒前
忧郁的萃发布了新的文献求助20
2秒前
芋圆完成签到,获得积分10
2秒前
2秒前
Jacky77发布了新的文献求助20
2秒前
2秒前
AJY完成签到,获得积分10
2秒前
FashionBoy的应助被天真依白采纳,获得10
3秒前
缥缈凡旋完成签到,获得积分10
3秒前
hswhswqkdh发布了新的文献求助10
3秒前
4秒前
zu完成签到,获得积分10
4秒前
乐观发布了新的文献求助10
4秒前
juphen2发布了新的文献求助10
4秒前
4秒前
三倍体杂交土豆人完成签到,获得积分10
4秒前
昵称完成签到,获得积分10
4秒前
yaya发布了新的文献求助10
4秒前
慕苡发布了新的文献求助10
4秒前
4秒前
4秒前
积极的冰真完成签到,获得积分20
5秒前
yangyanan的应助被林中鸟采纳,获得10
5秒前
清晨的小鹿完成签到,获得积分10
5秒前
111发布了新的文献求助10
5秒前
5秒前
coco发布了新的文献求助10
6秒前
充电宝的应助被冷傲的罡采纳,获得10
6秒前
Emma完成签到,获得积分10
6秒前
鱼鹰发布了新的文献求助30
6秒前
childe发布了新的文献求助10
6秒前
天真的日记本完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180807
求助须知:如何正确求助?哪些是违规求助? 9570895
关于积分的说明 21815089
捐赠科研通 7777155
什么是DOI,文献DOI怎么找? 3433347
关于科研通互助平台的介绍 2557613
邀请新用户注册赠送积分活动 2479317